Ulrich Grau, Ph.D.

Dr. Ulrich Grau serves as Enzon Pharmaceuticals’ chief scientific officer. In this role, Dr. Grau is responsible for advancing the Company’s product pipeline and expanding its research and development programs. 

Having directed numerous R&D programs, Dr. Grau brings over 20 years of experience from the biotechnology and pharmaceutical industry. His extensive expertise in the healthcare field includes corporate strategy and strategic alliances, program expansion, the development of new products and technologies for a variety of treatments.

Dr. Grau served as president of research and development at BASF Pharma where he directed a global R&D organization of approximately 1,500 employees and significantly advanced and expanded the Company’s product portfolio. This included therapies for a variety of health conditions, including rheumatoid arthritis, obesity, arrhythmia, sepsis and severe pain as well as participation in strategic alliances.  

Dr. Grau served as senior vice president and R&D integration officer for Aventis Pharma subsequent to the merger announcement between HMR and RPR.

Dr. Grau served as senior vice president, Global Product Realization at Hoechst Marion Roussel where he directed the company’s late-stage product development activities with a portfolio of projects ranging from diabetes, infectious diseases, oncology, osteoporosis, cardiology and rheumatology to hormone replacement therapies. Serving in numerous capacities at Hoechst, Dr. Grau developed research and educational programs, products and technologies and participated in strategic alliances. 

Born in Stuttgart, Germany, Ulrich received his PhD in chemistry and biochemistry from the University of Stuttgart and spent three years as a post doc at Purdue University.